C-MU2KNRG Therapeutics
mitochondrial biology, mPTP inhibition, oral small molecules
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-MU2K
C-MU2KC-MU2Kmitochondrial biology, mPTP inhibition, oral small molecules
0-100 chain-logic scale · 15 dimensions · scored on public evidence
NRG Therapeutics mitochondrial biology, mPTP inhibition, oral small molecules
NRG Therapeutics is a clinical stage neuroscience drug discovery company developing treatments for neurodegenerative disorders. Its pipeline focuses on disease-modifying drug candidates intended to rectify mitochondrial function and slow or halt progression of diseases such as ALS/MND and Parkinson's. The company states that its first-in-class, CNS-penetrant oral small molecules inhibit the mitochondrial permeability transition pore through a novel mechanism of action. Its lead candidate NRG5051 commenced a first-in-human clinical trial in 2026.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
NRG Therapeutics — Translational · Bottom quartile. Derived deterministically from 3 extracted project(s). Most-advanced status: phase 1. Band: translational. Aging-relevance not LLM-reviewed in this pass.
Source: Deterministic